Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track HUMA with free AI briefings, catalyst countdowns, and dilution alerts.

HUMA · Humacyte, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$79.9M Cash on Hand

10.2mo Cash Runway

Follow HUMA by email Get an email when HUMA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HUMA, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jun 2027 · Phase 3 · Active Trial · To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage
Registry primary completion date, not a results date
Dec 2028 · Phase 3 · Upcoming Trial · An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in
Registry primary completion date, not a results date
Sep 2030 · Phase 4 · Upcoming Trial · Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting
Registry primary completion date, not a results date
Sep 2030 · Phase 2 · Upcoming Trial · Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Acellular Tissue Engineered Vessel	Vascular Injury	Phase 4 · NCT07762794	Not yet recruiting
Human Acellular Vessel (HAV)	Renal Failure	Phase 3 · NCT02644941	Completed
Hepatitis A Virus	Renal Failure	Phase 2 · NCT04135417	Completed
Humacyte Coronary Tissue Engineered Vess	Coronary Artery Disease	Phase 2 · NCT07730528	Not yet recruiting
HAVG	End-stage Renal Disease	Phase 1 · NCT01840956	Completed
HAV implantation	Trauma	N/A · NCT05873959	Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HUMA holds $79.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $23.6M/quarter from operations, an estimated runway of 10.2 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HUMA files for a raise →

Get the full HUMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HUMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z